Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
36 results about "Myocardial ischemia/hypoxia" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Blood deficiency in the myocardium caused by a constriction or obstruction of its blood vessels; frequently occurs in conjunction with hypoxia, which is reduction in oxygen supply.
Application of ilexsaponin compound
InactiveCN102499926AOrganic active ingredientsCardiovascular disorderMyocardial ischemia/hypoxiaMedicine
The invention relates to application of an ilexsaponin compound, in particular to application of a pentacyclic triterpenoid ilexsaponin compound to medicines for preparing cardiovascular diseases caused by myocardial ischemia and anoxia, and belongs to the field of medicines. The ilexsaponin compound is shown by a formula as the specification, wherein R is H or beta-D-glucose, and a structural formula of the beta-D-glucose is shown in the specification.
Owner:刘国樵
Medicinal composition for curing cardiovascular diseases
The invention belongs to the technical field of medicaments or foods and discloses a medicinal composition. The medicinal composition comprises the following raw materials in part by weight: 10 to 1,000 parts of rhodioloside and 1 to 200 parts of D-ribose. The medicinal composition of the invention has a therapeutical effect on myocardial ischemia and anoxia, also can improve cardiovascular functions, controls the accumulation of blood platelets and the formation of thrombus, and has a certain effect of reducing blood lipid. The medicinal composition of the invention has the effects of tonifying qi, invigorating blood circulation, promoting coronary circulation and relieving pain, is used for chest obstruction which is caused by qi deficiency and blood stasis and is manifested as chest stuffiness, stabbing pain or dull pain, palpitation, short breath, fatigue, acratia, lack of qi and no desire to speak, light-headedness and the like, and is used for coronary heart disease and angina pectoris with above expressions.
Owner:杜超峰
Orally disintegrating tablet of gypenosides and its preparation process
InactiveCN1602882AQuality improvementEasy to takeOrganic active ingredientsMetabolism disorderOrally disintegrating tabletPalpitations
The invention relates to a jiaogulan total saponin orally-disintegrating tablet, having the effects of reducing blood fat, improving myocardial anoxia and ischemia, etc, able to nourish heart and tonify spleen, benefit vital energy and promote blood circulation, etc, and applied to cure high lipemia and its preparing method, deficiency of vital energy such as palpitation and being short of breath, choking sensation in chest and limb anaesthesia, phlegm blocking and blood stagnation, and other symptoms, and its preparing technique. The invention provides a convenient-taken, quickly absorbed and taking-effect jiaogulan total saponin orally-disintegrating tablet and its preparing technique, using jiaogulan total saponin as raw material, using filling agent, disintegrant, flavor correcting agent, flowing aid, lubricant, etc as auxiliaries, able to use adhesive or coating according to different conditions and also able to add in a proper amount of effervescing agent according to the conditions, preparing by specific preparing method, and pressing into tablets by tablet presser and making it. It has the characters of good brittleness, quick disintegration, good taste, low production cost, convenience for carrying, storing, transporting, taking, etc; especially, it can be taken without water and quickly take effect, thus improving the compliance of patients and strengthening curative effect of drug.
Owner:COSCI MED TECH CO LTD
Medicine for treating coronary heart disease and preparation method of medicine
InactiveCN105596979AEffective treatmentFunctional sedationDispersion deliveryInanimate material medical ingredientsAconitum carmichaeliSargent gloryvine
The coronary atherosclerotic heart disease is a heart disease of myocardial ischemia, anoxia or necrosis caused by vessel lomen stenosis or blocking resulted from atherosclerosis lesions of coronary artery blood vessels, and is often called as 'coronary disease'. The coronary disease further includes embolism stenosis or blocking caused by inflammation and embolism. The disease has remarkable regional difference, that is, the disease rates of northern provinces and cities are generally higher than those of southern provinces and cities. The medicine is prepared from medicines including lotus seeds, semen litchi, glutinous rice, allium macrostemon, lily, sandalwood, radix ophiopogonis, ligusticum wallichii, corydalis tuber, sargent gloryvine, radix paeoniae alba, tea tree roots, dates, puffball, American ginseng, aquilaria sinensis, lucid ganoderma, caragana sinica roots, dragon bone, patrinia scabiosaefolia, amber, radix angelicae pubescentis, platycladi seeds, harlequin glorybower leaves, spina date seeds, asarum, pseudo-ginseng, myrrh, trogopterus dung, carthamus tinctorius, fructus evodiae, polygonum cuspidatum, arillus longan, radix curcumae and aconitum carmichaeli. Due to the effects of the combined medicines, a synergistic effect can be achieved, and thus the coronary heart disease can be effectively treated.
Owner:薛学明
7,4'-di(mono succinate)o-ethoxy-daidzein and novel medical uses thereof
InactiveCN101255149AImprove pharmacological activitySmall side effectsOrganic active ingredientsNervous disorderDaidzeinPituitrin
The invention discloses new pharmaceutical uses of 7, 4'- di(mono succinate) oxyethoxypropyl daidzein. Pharmacological activity research is carried out to DZ5 by an experimental model for mice under atmospheric hypoxia tolerance, an experimental model for mice acute cerebral ischemia, an experimental model for bilateral common carotid arteries and vagus nerve ligation, an experimental model for mice KCN poisoning, an experimental model for mice NaNO2 poisoning and experimental model for learning and remembering, an action model for rat cortical neuron damage caused by anoxia of DZ5, an effect model for rat myocardial ischemia caused by hypophysin, an experimental model for vitro anti platelet aggregation, an experimental model for vivo anti platelet aggregation, and an effect model for arterial thrombosis in rabbits. Proved by the result, DZ5 has the functions of anti-cerebral ischemia and anoxia, anti-myocardial ischemia and anoxia, antagonistic memory disorders, anti-platelet aggregation and thrombosis, and protection of rat cortical neuron damage caused by anoxia. DZ5 can be mixed with a pharmacologically acceptable carrier or excipient to prepare medicine compositions.
Owner:SHENYANG PHARMA UNIVERSITY
Method for preparing preparation used for treating coronary atherosclerotic heart disease
InactiveCN104042912AAnthropod material medical ingredientsCardiovascular disorderCoronary arteriesMyocardial ischemia/hypoxia
The invention relates a method for preparing a preparation used for treating a coronary atherosclerotic heart disease. The coronary atherosclerotic heart disease is heart disease caused by myocardial ischemia and anoxia as a vessel lomen is blocked owning to coronary atherosclerosis; the coronary atherosclerotic heart disease and coronary artery functionality change (spasm) are called by a joint name of a coronary heart disease which is called coronary heart disease for short and is also called an ischemic heart disease. The method for preparing the preparation used for treating the coronary atherosclerotic heart disease has the advantages that the traditional Chinese medicinal theory is applied and combined with the modern biotechnology for preparing traditional Chinese medicinal materials, heart and blood vessels are regulated, stasis is removed and blood is activated, and blood vessels are softened; qi and blood are tonified comprehensively, purgation-tonifying is realized, heart is strengthened, collaterals are activated, and immunity is regulated, so that the coronary atherosclerotic heart disease is comprehensively treated.
Owner:CHONGZHOU DILONG HAILONG BIOLOGICAL PRODS DEV INST
Anti-myocardial ischemia hypoxia polypeptide, composition and application thereof, and polypeptide drug
The invention relates to an anti-myocardial ischemia hypoxia polypeptide, a composition and an application thereof, and a polypeptide drug. The sequence of the anti-myocardial ischemia hypoxia polypeptide has an amino acid sequence shown in SEQ ID NO.1, or has an amino acid sequence which has at least 70% of homology with the amino acid sequence shown in SEQ ID NO.1. The anti-myocardial ischemia hypoxia polypeptide can significantly reduce the activity level and release of lactate dehydrogenase in cells, and can play a role in protecting the cells; meanwhile, the anti-myocardial ischemia hypoxia polypeptide can remarkably improve the cell survival rate under the hypoxia condition. Animal experiments show that the polypeptide can significantly reduce lactic dehydrogenase (LDH) and creatinekinase (CK) in rat serum, has a significant protective effect on myocardial cell ischemia injury, prevents and / or treats coronary atherosclerotic heart disease, and reduces the death rate of myocardial infarction.
Owner:SHANGHAI TONGREN HOSPITAL
Crocin yeast microcapsule and preparation method for same
ActiveCN106074449AIntegrity guaranteedGuaranteed activityNervous disorderElcosanoid active ingredientsWater bathsFreeze-drying
The invention discloses a crocin yeast microcapsule and a preparation method for the same. Freeze-dried powder prepared by extraction, purification and freeze drying of fructus gardeniae fruits is taken as a core material, yeast cells are taken as an embedding wall material, and a yeast microcapsule product is prepared by thermostatic water bath oscillation, centrifugation and freeze drying. Not only are the characteristics of myocardial ischemia and anoxia resistance, behavioral perception improvement, lipid peroxidation resistance, atherosclerosis resistance, tumor resistance and the like of crocin maintained, but also a solution is provided for the problem of relatively lower absorption rate of the crocin, and the stability of the crocin is improved; a dry powdery microcapsule is easier to store and use; the yeast microcapsule with the characteristics of safety, nontoxicity, rich nutrients and the like also has advantages in application to preparation of food and medicaments.
Owner:XIAMEN TASMAN BIO TECH
Medicine for treating coronary heart disease and preparation method thereof
InactiveCN102048809ALess drug componentsCardiovascular disorderPlant ingredientsSalvia miltiorrhizaCoronary artery disease
The invention relates to a medicine for treating coronary heart disease and a preparation method thereof. The medicine is prepared by the following raw materials in percentage by weight: 3-6 of rhodiola root, 3-6 of salvia miltiorrhiza, 2-4 of Ziziphora bungeana and 1-3 of lignum dalbergiae odoriferae, and the ingredients of the raw materials are extracted and then used together with other auxiliary materials to be prepared into granules or capsules. The medicine for treating coronary heart disease has less medicinal ingredients, definite curative effect, and the effects of improving symptom of myocardial ischemia, improving the ECG (electrocardiogram), preventing platelet aggregation, dilating the blood vessel and improving the life quality of patients with coronary heart disease and angina pectoris.
Owner:安冬青
Application of 5,6,7,8- trihydroxy-8-methoxyflavone in preparing anti-hypoxic drug
ActiveCN103877074ASignificant anti-hypoxic effectGood effectOrganic active ingredientsAntinoxious agentsDiseaseCerebral ischaemia
The invention discloses an application of 5,6,7,8- trihydroxy-8-methoxyflavone in preparing an anti-hypoxic drug which is the drug for preventing and treating hypoxic injury diseases; the hypoxic injury diseases are high-altitude low-pressure oxygen deficit-caused acute high altitude diseases, cerebral ischemia hypoxic diseases or myocardial ischemia hypoxic diseases. The application has beneficial effects as follows: an experiment proves that the 5,6,7,8- trihydroxy-8-methoxyflavone has a remarkable anti-hypoxic effect, and an effect tending to be better than that of acetazolamide; the anti-hypoxic drug prepared by applying the 5,6,7,8- trihydroxy-8-methoxyflavone as an active ingredient can be used for preventing and treating hypoxic injuries or treating various hypoxic pathological states caused by oxygen content drop in external environment, also can be used for preventing or treating hypoxic pathological states of heart, brain, respiratory system, and the like as external normal oxygen cannot sufficiently get to a body due to diseases, and the like, and further can be used for preventing or treating the pathological state that relative oxygen supply is insufficient as oxygen consumption needed for activities of the body exceeds physiological mobilization ability.
Owner:中国人民解放军联勤保障部队第九四〇医院
Application of chrysin in preparing anti-hypoxic drug
ActiveCN103877075ASignificant anti-hypoxic effectGood effectOrganic active ingredientsAntinoxious agentsDiseaseCerebral ischaemia
The invention discloses an application of chrysin in preparing an anti-hypoxic drug. The anti-hypoxic drug is a drug for preventing and treating hypoxic injury diseases which are high-altitude low-pressure oxygen deficit-caused acute high altitude diseases, cerebral ischemia hypoxic diseases or myocardial ischemia hypoxic diseases. The application has beneficial effects as follows: experiments prove that the chrysin has a remarkable anti-hypoxic effect, and effect tending to be better than that of acetazolamide; the anti-hypoxic drug prepared by applying the chrysin as an active ingredient can be used for preventing and treating hypoxic injuries or treating various hypoxic pathological states caused by oxygen content drop in external environment, also can be used for preventing or treating hypoxic pathological states of heart, brain, respiratory system, and the like as external normal oxygen cannot sufficiently get to a body due to diseases, and the like, and further can be used for preventing or treating the pathological state that relative oxygen supply is insufficient as oxygen consumption needed for activities of the body exceeds physiological mobilization ability.
Owner:中国人民解放军联勤保障部队第九四〇医院
Pharmaceutical use of vitexin for anti-myocardial ischemia action
InactiveCN1935150AHas anti-myocardial ischemia effectOrganic active ingredientsCardiovascular disorderHeart muscle extractMyocardial ischemia/hypoxia
The present invention relates to a vitexin with the action for resisting myocardial ischemia, belonging to the field of Chinese medicine technology. Said vitexin is effective component extracted from Chinese medicinal material crataegus leaf.
Owner:合肥七星医药科技有限公司
Chinese-medicinal preparation for treating cardiovascular and cerebrovascular disease and its making method
InactiveCN1895392AReduce oxygen consumptionLow viscosityPharmaceutical non-active ingredientsCapsule deliveryDiseaseHeart muscle extract
A Chinese medicine in the form of capsule for treating cardiovascular and cerebrovascular diseases, especially the myocardial is chemia and anoxia, is composed of capsule body and medicine. Said medicine is proportionally prepared from the extract of haw leaf, polyethanediol 400 and PVP K90 through mixing, loading in capsules, sealing, and drying.
Owner:YUANTONG BIOLOGICAL MEDICAL SHANGHAI
Anti-myocardial ischemia hypoxia polypeptide, composition and application thereof, and polypeptide drug
The invention relates to an anti-myocardial ischemia hypoxia polypeptide, a composition and an application thereof, and a polypeptide drug. The sequence of the anti-myocardial ischemia hypoxia polypeptide has an amino acid sequence shown in SEQ ID NO.1, or has an amino acid sequence which has at least 70% of homology with the amino acid sequence shown in SEQ ID NO.1. The anti-myocardial ischemia hypoxia polypeptide can significantly reduce the activity level and release of lactate dehydrogenase in cells, and can play a role in protecting the cells; meanwhile, the anti-myocardial ischemia hypoxia polypeptide can remarkably improve the cell survival rate under the hypoxia condition. Animal experiments show that the polypeptide can significantly reduce lactic dehydrogenase (LDH) and creatinekinase (CK) in rat serum, has a significant protective effect on myocardial cell ischemia injury, prevents and / or treats coronary atherosclerotic heart disease, and reduces the death rate of myocardial infarction.
Owner:SHANGHAI TONGREN HOSPITAL
Traditional Chinese medicine preparation for treating angina pectoris of coronary heart disease
InactiveCN105582280AQuick resultsShort course of treatmentHydroxy compound active ingredientsOrganic non-active ingredientsMonkshoodsMyrrh
The invention discloses a traditional Chinese medicine preparation for treating angina pectoris of the coronary heart disease. A medicine for oral use comprises fructus trichosanthis, pinellia tubers, immature bitter orange, cassia twigs, platycodon roots, danshen roots, prepared common monkshood daughter roots, dried rehmannia roots, unibract fritillary bulb, peach kernels, safflower, szechuan lovage rhizomes, pearl powder, pseudo-ginseng powder and sea-ear shell; an externally-applied medicine comprises alum, rhubarb, frankincense, myrrh, rhizoma corydalis, largetrifoliolious bugbane rhizomes, borneol, musk and turmeric root-tuber. The traditional Chinese medicine is excellently compatible and adopts a reasonable formula; the medicine for oral use and the externally-applied medicine are jointly used and perform the efficacy of warming yang, benefiting qi and promoting blood circulation to remove blood stasis; blood activating and qi replenishment and qi circulation promotion are matched, stasis removal and blood nourishment and production are realized simultaneously, ascending and descending are considered, the heart-qi is sufficient through qi benefiting and blood activation, force for pushing blood to circulate is increased, the blood circulates smoothly, qi and blood are harmonious, the blood supply function of the coronary artery is balanced on a new basis, cardiac microcirculation is improved, myocardial ischemia is relieved, and accordingly, angina pectoris is relieved or even eliminated.
Owner:李宪秋
Clerodane diterpenoid compounds and application thereof in pharmacy
The invention discloses Clerodane diterpenoid compounds shown in 1-6 structural formulas, a pharmaceutical composition taking the Clerodane diterpenoid compounds 1-6 as effective components, a preparation method thereof and application thereof in preparing myocardial protection drugs. Pharmacological activity tests show the the compounds 1-6 can obviously increase the survival rate of myocardial cells, and at the same time, the compounds 1-6 are found to have better protective effect on H2O2-induced primary myocardial cell injury in neonatal rats, and the protective effect shows concentrationdependence. The research results show the the compounds can be developed into drugs for myocardial cell protection, and can be used for preventing and treating cardiovascular diseases such as coronaryheart disease, angina pectoris, myocardial infarction, myocarditis, arrhythmia and the like caused by myocardial ischemia and hypoxia.
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI
Application of 5,6,7,8- tetrahydroxyflavone in preparing anti-hypoxic drug
ActiveCN103877076ASignificant anti-hypoxic effectPrevention or treatment of hypoxic pathological stateOrganic active ingredientsAntinoxious agentsDiseaseMyocardial ischemia/hypoxia
The invention discloses a novel use of 5,6,7,8- tetrahydroxyflavone, namely an application in preparing an anti-hypoxic drug. The anti-hypoxic drug prepared by the 5,6,7,8- tetrahydroxyflavone has obvious anti-hypoxic activity, and can be used for preventing or treating high-altitude low-pressure oxygen deficit-caused acute high altitude diseases, cerebral ischemia hypoxic diseases or myocardial ischemia hypoxic diseases.
Owner:中国人民解放军联勤保障部队第九四〇医院
Heart intervention catheter butt joint bracket
The invention discloses a heart intervention catheter butt joint bracket which comprises a main body plate, wherein the upper surface of the main body plate close to the front side is provided with a straight-shaped butt joint groove which penetrates through two ends of the main body plate is arranged on the main body plate and close to the front side of the main body plate; a front inclined plate inclining upwards is arranged on the butt joint groove and the main body plate in the front; and the middle part of the butt joint groove is provided with a butt joint mark. The heart intervention catheter butt joint bracket provided by the invention has the advantages that in use, a catheter and a guide wire interface are bidirectionally placed in a groove on the bracket, the mutual butt joint operation is carried out by utilizing the guide effect of the groove, and the operation is successful at one time; the device is simple in manufacturing, materials are easy to get, the volume is small, the manufacturing cost is low, the operation conditions are not restricted, and the catheter sacculus and the bracket can not be damaged; the operation time is saved, thus myocardial ischemia and oxygen deficiency for patients is reduced, and the heat functions are improved; and meanwhile, the energy and physical agility of surgeons are saved as much as possible, the essential conditions for the successful surgery are provided, and the working efficiency is improved.
Owner:HARBIN MEDICAL UNIVERSITY
Medicine composition for treating cardiovascular and cerebrovascular diseases caused by qi stagnation blood stasis, preparation method and application thereof
InactiveCN1907327AReduce vitalityLess oxygen consumptionPill deliveryCapsule deliveryPANAX NOTOGINSENG ROOTMyocardial ischemia/hypoxia
The invention relates to a medicinal composition for improving blood circulation and relieving stasis, wherein the composition is prepared from the following raw materials (by weight portion): panax notoginseng saponins 10-200 parts, red sage root 125-2500 parts, the invention also relates to the process for preparing the composition and use thereof.
Owner:HEBEI ZHAOKANG PHARMACY
Application of chrysin in the preparation of anti-hypoxic drugs
ActiveCN103877075BSignificant anti-hypoxic effectGood effectOrganic active ingredientsAntinoxious agentsDiseaseMyocardial ischemia/hypoxia
The invention discloses the application of chrysin in the preparation of anti-hypoxic drugs. The anti-hypoxic drugs are drugs for preventing and treating hypoxic damage diseases, and the hypoxic damage diseases are acute high altitude sickness, cerebral Ischemic-hypoxic disease or myocardial ischemic-hypoxic disease. The beneficial effects of the present invention are as follows: it is proved by experiments that chrysin has a significant anti-hypoxic effect, and the effect tends to be better than that of acetazolamide. Injury or treatment of various hypoxic pathological states caused by the reduction of oxygen content in the external environment. It can also be used to prevent or treat diseases that cause normal oxygen in the outside world to not fully reach the body, resulting in hypoxic pathology such as the heart, brain and respiratory system. It can also be used to prevent or treat the pathological state of relative oxygen supply deficiency caused by the oxygen consumption required by body activities exceeding the physiological mobilization capacity.
Owner:中国人民解放军联勤保障部队第九四〇医院
Anti-myocardial ischemia-hypoxia polypeptide, composition and application thereof, and polypeptide drug
Owner:SHANGHAI TONGREN HOSPITAL
A class of Crotane-type diterpene compounds and their application in pharmacy
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI
Application of Lei Gonglian Extract in Preparation of Anti-myocardial Ischemia and Hypoxia Products
ActiveCN104887880BHigh activityImprove performanceCardiovascular disorderPlant ingredientsAcute myocardial ischaemiaIschemic hypoxia
Owner:贵州中医药大学
Application of HIF-1 alpha degradation inhibitor in preparation of drug for coronary heart disease with increased ketone body level
PendingCN112741834AReduced hypoxic damageReliable methodOrganic active ingredientsCardiovascular disorderMyocardial ischemia/hypoxiaPharmaceutical drug
The invention discloses application of an HIF-1 alpha degradation inhibitor roxostat in preparation of a drug for coronary heart disease with increased ketone body level. HIF-1 alpha is taken as a target spot, the roxostat is clinically applied to inhibit HIF-1 alpha degradation and increase the HIF-1 alpha level, and myocardial ischemia and hypoxia injury mediated by increase of the ketone body level can be improved. The roxostat is clinically applied to treatment of ischemic heart disease, especially to patients with coronary heart disease with increased blood ketone body level, so as to reduce myocardial cell injury.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV
Application of 5,6,7-trihydroxy-8-methoxyflavone in the preparation of anti-hypoxic drugs
ActiveCN103877074BSignificant anti-hypoxic effectGood effectOrganic active ingredientsAntinoxious agentsDiseaseBULK ACTIVE INGREDIENT
Owner:中国人民解放军联勤保障部队第九四〇医院
Medicine composition for treating cardiovascular and cerebrovascular diseases caused by qi stagnation blood stasis, preparation method and application thereof
InactiveCN1907327BWith promoting blood circulation and removing blood stasisWith regulating qi and relieving painPill deliveryCapsule deliveryPANAX NOTOGINSENG ROOTMyocardial ischemia/hypoxia
The invention relates to a medicinal composition for improving blood circulation and relieving stasis, wherein the composition is prepared from the following raw materials (by weight portion): panax notoginseng saponins 10-200 parts, red sage root 125-2500 parts, the invention also relates to the process for preparing the composition and use thereof.
Owner:HEBEI ZHAOKANG PHARMACY
Capsule for treating qi-yin deficiency type coronary heart disease angina, and preparation method of capsule
PendingCN113069518AImprove symptoms of ischemia and hypoxiaEnhance pharmacological effectsUnknown materialsCapsule deliveryRadix Astragali seu HedysariSaposhnikovia
The invention specifically relates to a capsule for treating qi-yin deficiency type coronary heart disease angina, and a preparation method of the capsule, and belongs to the technical field of medicines. In order to solve the technical problem, the invention provides the capsule for treating the qi-yin deficiency type coronary heart disease angina, and the preparation method of the capsule. The invention adopts the technical scheme that the capsule comprises the following raw materials in parts by weight: 50-90 parts of radix salviae miltiorrhizae, 80-140 parts of radix astragali, 25-70 parts of fructus psoraleae, 50-70 parts of radix codonopsitis, 30-50 parts of poria cocos, 15-35 parts of rhizoma paridis, 35-60 parts of radix saposhnikoviae, 50-65 parts of radix paeoniae rubra, 20-30 parts of radix polygalae, 15-30 parts of semen alpiniae katsumadai, 10-35 parts of axillary choerospondias fruits, 30-50 parts of Ardisia densilepidotula Merr., 10-20 parts of Solms-Laubachia lanata Botsch., 10-30 parts of prepared glycyrrhizae radix, 20-30 parts of Platanthera minor (Miq.) Reichb. f. herba, 12-25 parts of Squama Manis pieces, 20-32 parts of caulis spatholobi, 10-28 parts of herba lycopi and 15-25 parts of folium ginkgo. The capsule is characterized in that all medicines are combined to effectively eliminate the symptom of myocardial ischemia and anoxia, and the capsule is used for treating the qi-yin deficiency type coronary heart disease angina.
Owner:山西华元医药生物技术有限公司
Orally disintegrating tablet of gypenosides and its preparation process
InactiveCN1263457CQuality improvementEasy to takeOrganic active ingredientsMetabolism disorderAdhesivePalpitations
The invention relates to a jiaogulan total saponin orally-disintegrating tablet, having the effects of reducing blood fat, improving myocardial anoxia and ischemia, etc, able to nourish heart and tonify spleen, benefit vital energy and promote blood circulation, etc, and applied to cure high lipemia and its preparing method, deficiency of vital energy such as palpitation and being short of breath, choking sensation in chest and limb anaesthesia, phlegm blocking and blood stagnation, and other symptoms, and its preparing technique. The invention provides a convenient-taken, quickly absorbed and taking-effect jiaogulan total saponin orally-disintegrating tablet and its preparing technique, using jiaogulan total saponin as raw material, using filling agent, disintegrant, flavor correcting agent, flowing aid, lubricant, etc as auxiliaries, able to use adhesive or coating according to different conditions and also able to add in a proper amount of effervescing agent according to the conditions, preparing by specific preparing method, and pressing into tablets by tablet presser and making it. It has the characters of good brittleness, quick disintegration, good taste, low production cost, convenience for carrying, storing, transporting, taking, etc; especially, it can be taken without water and quickly take effect, thus improving the compliance of patients and strengthening curative effect of drug.
Owner:COSCI MED TECH CO LTD
Anti-myocardial ischemia-hypoxia polypeptide, composition and application thereof, and polypeptide drug
The invention relates to an anti-myocardial ischemia-hypoxia polypeptide, composition, application thereof and polypeptide medicine. Wherein, the sequence of the anti-myocardial ischemia-hypoxic polypeptide has: the amino acid sequence shown in SEQ ID NO.1, or has at least 70% homology with the amino acid sequence shown in SEQ ID NO.1 amino acid sequence. The above-mentioned anti-myocardial ischemia-hypoxia polypeptide can significantly reduce the activity level and release of lactate dehydrogenase in cells, and can protect cells; at the same time, the anti-myocardial ischemia-hypoxia polypeptide can significantly improve cell survival under hypoxia Rate. Animal experiments show that the polypeptide can significantly reduce lactate dehydrogenase (LDH) and creatine kinase (CK) in rat serum, and has a significant protective effect on myocardial cell ischemic injury, preventing and / or treating coronary atherosclerosis Sclerotic heart disease, reduce the mortality rate of myocardial infarction.
Owner:SHANGHAI TONGREN HOSPITAL
Dual drug composition, capsule drug, tablet drug and application of dual drug composition
PendingCN111714488APromote collateral circulationNervous system toxicity reliefOrganic active ingredientsNervous disorderSalidrosideFormulary
The invention relates to a treatment of myocardial necrosis caused by myocardial ischemia and anoxia caused by cardiovascular clogging caused by coronary atherosclerosis in the coronary heart disease,and provides a new practical dual drug composition for addressing both symptoms and root causes other than surgery and application of the dual drug composition. The dual drug composition comprises plant extracts of lithospermic acid B and salidroside. The binary drug composition is applied to prepare drugs for drug pass for treating coronary artery. The dual drug composition disclosed by the invention achieves the drug pass effect by opening and promoting collateral circulation, and addresses both symptoms and root causes, is simple to take, and solves all short-term and long-term problems inrevascularization treatment at present.
Owner:张维
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com